Back

Frailty, initial attrition and the potential use of novel platinum-free options for non-small-cell lung cancer in the real-world setting

2026-02-03 oncology Title + abstract only
View on medRxiv
Show abstract

BackgroundOlder age and comorbidities complicate initial therapy in non-small-cell lung cancer (NSCLC), as platinum ineligibility has not been systematically characterized. MethodsAll 2592 patients presenting with metastatic NSCLC between 2018-2023 at Thoraxklinik Heidelberg were analyzed. ECOG status (PS), comorbidities, molecular testing, therapy, toxicities, and outcomes were verified from individual patient records. ResultsAmong 1306 patients with PD-L1 0-49%, systemic therapy was initiate...

Predicted journal destinations